Prognostic value of CHD family members in breast cancer

Abstract

Regarding the variety of symptoms experienced by breast cancer (BC) patients and the unknown etiology of the disease, the identification of a prognostic marker can effectively help in the early detection and treatment of BC. Using bioinformatic research, the prognostic value of the chromodomain helicase DNA-binding family (CHD) was assessed in BC detection. All nine members of this gene family are chromatin regulators. Changes in chromatin compression and access to cellular machinery are associated with CHD proteins. These proteins are involved in cell proliferation and transcription as well as DNA damage repair. This gene family plays a decisive role in cancer development. Our UALCAN investigation indicated substantial downregulation of CHD2 and CHD9 in tumor tissues. Large mRNA expression of CHD2 and CHD8 has been also linked to superior OS and RFS, according to Kaplan-Miere curves. Moreover, a higher SBR grade was associated with lower CHD2, CHD8, CHD9, and CHD7 mRNA levels, while a lower SBR grade was linked to higher CHD7 mRNA levels. Based on the clinic-pathological findings, the mRNA levels of CHD2, CHD8, and CHD9 were lower in ER-negative, PR-negative, triple-negative, and basal-like BC, while CHD7 was higher. CHD2, CHD7, CHD8, and CHD9 mutations were detected in 8%, 15%, 7%, and 11% of BC patients, respectively, according to genetic alteration analyses in the cBioportal database. TIMER also found a link between CHD2, CHD8, and CHD9 and the infiltration of CD8+ T cells, neutrophils, and macrophages. These findings suggest CHD2, CHD7, CHD8, and CHD9 genes as promising breast cancer prognostic markers.